Azenta (NasdaqGS:AZTA) - Share price, News & Analysis

AZTA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

AZTA Stock Overview

Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide.

Rewards

Trading at 34.5% below our estimate of its fair value

Revenue is forecast to grow 19.87% per year

Risk Analysis

Earnings are forecast to decline by an average of 89.9% per year for the next 3 years

Azenta Competitors

Thermo Fisher Scientific

NYSE:TMO

US$211.1b

ASML Holding

ENXTAM:ASML

€210.9b

Tokyo Electron

TSE:8035

JP¥9.3t

Laboratory Corporation of America Holdings

NYSE:LH

US$22.5b

Price History & Performance

Summary of all time highs, changes and price drops for Azenta
Historical stock prices
Current Share Price	US$70.73
52 Week High	US$124.79
52 Week Low	US$61.35
Beta	1.66
1 Month Change	-9.39%
3 Month Change	-18.93%
1 Year Change	-24.52%
3 Year Change	97.13%
5 Year Change	159.18%
Change since IPO	607.30%

Shareholder Returns

	AZTA	US Life Sciences	US Market
7D	1.3%	4.6%	2.7%
1Y	-24.5%	-6.6%	-8.1%

Return vs Industry: AZTA underperformed the US Life Sciences industry which returned -6.6% over the past year.

Return vs Market: AZTA underperformed the US Market which returned -8.1% over the past year.

Price Volatility

Is AZTA's price volatile compared to industry and market?
AZTA volatility
AZTA Average Weekly Movement	7.4%
Life Sciences Industry Average Movement	10.9%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: AZTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: AZTA's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1978	2,900	Steve Schwartz	https://www.azenta.com

Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils; instruments, such as labeling, bar coding, capping, de-capping, auditing, sealing, peeling, piercing tubes, and plates.

Azenta Fundamentals Summary

How do Azenta's earnings and revenue compare to its market cap?
AZTA fundamental statistics
Market Cap	US$5.64b
Earnings (TTM)	-US$23.20m
Revenue (TTM)	US$551.22m

9.6x

P/S Ratio

-227.0x

P/E Ratio

Is AZTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AZTA income statement (TTM)
Revenue	US$551.22m
Cost of Revenue	US$284.78m
Gross Profit	US$266.44m
Other Expenses	US$289.64m
Earnings	-US$23.20m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.31
Gross Margin	48.34%
Net Profit Margin	-4.21%
Debt/Equity Ratio	0%

How did AZTA perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

-64%

Payout Ratio

Valuation

Is Azenta undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

34.5%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: AZTA ($70.73) is trading below our estimate of fair value ($108.03)

Significantly Below Fair Value: AZTA is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: AZTA is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: AZTA is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AZTA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: AZTA is good value based on its PB Ratio (1.5x) compared to the US Life Sciences industry average (2.2x).

Future Growth

How is Azenta forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-89.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZTA's earnings are forecast to decline over the next 3 years (-89.9% per year).

Earnings vs Market: AZTA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AZTA's is expected to become profitable in the next 3 years.

Revenue vs Market: AZTA's revenue (19.9% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: AZTA's revenue (19.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AZTA's Return on Equity is forecast to be low in 3 years time (2.2%).

Past Performance

How has Azenta performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-50.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AZTA is currently unprofitable.

Growing Profit Margin: AZTA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AZTA is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.

Accelerating Growth: Unable to compare AZTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AZTA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).

Return on Equity

High ROE: AZTA has a negative Return on Equity (-0.67%), as it is currently unprofitable.

Financial Health

How is Azenta's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AZTA's short term assets ($3.0B) exceed its short term liabilities ($618.0M).

Long Term Liabilities: AZTA's short term assets ($3.0B) exceed its long term liabilities ($76.1M).

Debt to Equity History and Analysis

Debt Level: AZTA is debt free.

Reducing Debt: AZTA had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AZTA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AZTA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is Azenta current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.56%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: AZTA's dividend (0.57%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.51%).

High Dividend: AZTA's dividend (0.57%) is low compared to the top 25% of dividend payers in the US market (3.97%).

Stability and Growth of Payments

Stable Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: AZTA is not paying a notable dividend for the US market.

Cash Payout to Shareholders

Cash Flow Coverage: AZTA is paying a dividend but the company has no free cash flows.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average management tenure

CEO

Steve Schwartz (62 yo)

11.58yrs

Tenure

US$5,290,656

Compensation

Dr. Stephen S. Schwartz, also known as Steve, is a Director Azenta US, Inc. He is President and Chief Executive Officer at Azenta US, Inc. He has been Chief Executive Officer of Azenta, Inc. (formerly know...

CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD5.29M) is below average for companies of similar size in the US market ($USD8.19M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AZTA's management team is seasoned and experienced (7.8 years average tenure).

Board Members

Experienced Board: AZTA's board of directors are seasoned and experienced ( 10.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2022/03/31
Annual Earnings	2021/09/30